Creatinine modified <scp>C</scp>hild–<scp>T</scp>urcotte–<scp>P</scp>ugh and integrated model of end‐stage liver disease scores as predictors of spontaneous bacterial peritonitis‐related in‐hospital mortality: Applicable or not

Hassan, Elham Ahmed; Rehim, Abeer Sharaf El-Din Abdel

doi:10.1111/jgh.12918

Cited by 11 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the prevalence of SBP, it is difficult to make comparisons between bacterascites and culture‐negative SBP groups in the same cohort. Previous studies reported that the 1‐month or in hospital mortality in SBP patients (mean MELD score 18 or 19) was 17%‐25%, which was similar with the 28‐day mortality of bacterascites patients (mean MELD score 18) in our study. This suggests that bacterascites carries a substantial complication and mortality rate and that early diagnosis is the key step to improve clinical outcomes.…”

Section: Discussionsupporting

confidence: 88%

Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study

Gao

Wang

et al. 2020

Liver International

View full text Add to dashboard Cite

Background & Aims: Current guidelines on the management of bacterascites are limited. This multicentre, retrospective study investigated the clinical features and outcomes of cirrhosis patients with bacterascites. Methods: Two series of cirrhosis patients were evaluated. The first included 418 patients with ascites-positive cultures at 11 hospitals during 2012-2018. Clinical characteristics and outcomes were recorded. The second included 208 patients with sterile ascites from a prospective cohort (NCT02457637). Clinical features and outcomes of cirrhotic patients with or without bacterascites were investigated.Results: In the first series, bacterascites was diagnosed in 254/418 (60.8%) patients, and culture-positive spontaneous bacterial peritonitis (SBP) in 164/418 (39.2%) patients. Gram-positive bacteria were more prevalent in bacterascites patients than in culture-positive SBP patients (59.1% vs 22.0%; P < .001). For patients with acuteon-chronic liver failure (ACLF) in bacterascites and culture-positive SBP groups, the 28-day transplant-free mortality (41.3% vs 65.5%; P = .015) and the prevalence of inhospital acute kidney injury (AKI) (84.8% vs 75%; P = .224). For patients without ACLF

show abstract

Section: Discussionsupporting

confidence: 88%

Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study

Gao

Wang

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

“…Our literature search for relevant studies of SBP identified 17 publications (Table ) . The reported baseline clinical characteristics including age, gender distribution, and liver disease severity scores of SBP were comparable to those identified in our patient population with bacterascites.…”

Section: Resultsmentioning

confidence: 54%

Bacterascites: A study of clinical features, microbiological findings, and clinical significance

Oey

Buuren

Jong

et al. 2018

Liver International

View full text Add to dashboard Cite

BackgroundKnowledge about bacterascites is limited and management guidelines are based on small patient series. The purpose of this study was to add further insight into the clinical characteristics, microbiological findings, and prognosis of patients diagnosed with bacterascites.MethodsRetrospective analysis of patients with advanced chronic liver disease diagnosed with bacterascites and SBP between January 2003 and August 2016.ResultsIn this study, 123 patients were included with 142 episodes of bacterascites. The median MELD score was 20 and clinical symptoms of infection were present in 78%. Empiric antibiotic treatment was initiated in 68%. In 26 untreated patients undergoing repeated paracentesis, 42% were diagnosed with either ongoing bacterascites or SBP. The presence of signs or symptoms of infection was not an independent predictor for mortality or spontaneous resolution of infection. The 1‐month and 1‐year mortality rates of the 123 patients studied, were 32% and 60%, respectively; these results were in line with data pertaining to the prognosis of SBP.ConclusionsPatients with bacterascites and SBP are highly comparable with respect to severity of liver disease and overall prognosis. If left untreated, bacterascites is likely to persist or to evolve to SBP in a significant proportion of patients. The results of this study support current guidelines regarding the treatment of ascitic fluid infection, but could not confirm the prognostic relevance of symptomatic disease at the time of diagnosis. We suggest that the threshold to initiate antibiotic treatment, in particular in cases with severely advanced liver disease, should be low.

show abstract

“…SPB has a considerable mortality rate (Bellot et al . , Hassan & Abd El‐Rehim ). As the severity of liver disease increases, the signs and symptoms of decompensated cirrhosis become more debilitating and impede health‐related quality of life (Bajaj et al .…”

Section: Introductionmentioning

confidence: 99%

Factors associated with medication adherence in patients living with cirrhosis

Polis

Zang

Mainali

et al. 2015

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

Creatinine modified Child–Turcotte–Pugh and integrated model of end‐stage liver disease scores as predictors of spontaneous bacterial peritonitis‐related in‐hospital mortality: Applicable or not

Cited by 11 publications

References 31 publications

Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study

Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study

Bacterascites: A study of clinical features, microbiological findings, and clinical significance

Factors associated with medication adherence in patients living with cirrhosis

Contact Info

Product

Resources

About